NCT07145255 · MBrace Therapeutics
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
What this study is about
This is a conducted at multiple hospitals, where both patients and doctors know the treatment given FIH, Phase 1a (gradually increasing doses), Phase 1b (dose expansion) and Phase 2 study in patients with advanced metastatic solid tumors refractory to standard treatment.
View original scientific description
This is a multicenter, open-label FIH, Phase 1a (dose escalation), Phase 1b (dose expansion) and Phase 2 study in patients with advanced metastatic solid tumors refractory to standard treatment.
Interventions
DRUG
ADC
MBRC-201 ADC
Primary outcome measures
Type, incidence, severity, seriousness, and relatedness of adverse events (AEs)
Time frame: From Enrollment through treatment and long term follow-up (approximately 24 months)
• TEAEs will be graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v.5.0.
• Incidence and prevalence of Dose-limiting Toxicities (DLTs) and cumulative safety by dose level
Time frame: 21 days
The DLTs are specific adverse events and are defined as any of the following: high grade non-hematologic toxicity, hematologic toxicity, and Non-hematologic (laboratory) toxicities
Duration of Response (DOR)
Time frame: Approximately 24 months
will be defined as the time from the first documentation of an objective tumor response (CR or PR) to the first documentation of tumor progression or to death due to any cause, whichever comes first, whichever comes first as defined by RECIST version 1.1.
Disease Control Rate (DCR)
Time frame: Approximately 24 months
DCR will be defined as the proportion of patients with best overall response of CR, PR, or stable disease (SD), whichever comes first as defined by RECIST version 1.1.
Progression Free Survival (PFS)
Time frame: Approximately 24 months
PFS will be defined as the time from the start of any study treatment to first documentation of disease progression or to death due to any cause, whichever comes first as defined by RECIST version 1.1.
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Patients are eligible to be included in the study only if all of the following criteria apply: 1. Provide written consent on an informed consent form (ICF), approved by an Institutional Review Board (IRB)/Independent Ethics Committee (IEC), prior to any study-specific evaluation. Patients should have the ability to read and understand the ICF, ask for any clarifications from the study staff, and be able to comply with all planned study procedures. 2. 18 years of age or older at the time of informed consent. 3. Female patients must be at least 2 years postmenopausal (defined as 2 years without menses), surgically sterile (at least 6 months prior to dosing; must be documented) or patients of childbearing potential under the following conditions:
- Must be nonlactating and have a negative serum (preferred) or urine pregnancy test results within 72 hours prior to the first dose of MBRC-201.
- Must agree not to try to become pregnant during the study and for at l
Where
- San Francisco, California
- Grand Rapids, Michigan
- East Brunswick, New Jersey
- Irving, Texas
- San Antonio, Texas
- West Valley City, Utah
- Fairfax, Virginia
Related conditions & keywords
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Feb 17, 2026 · Source of record for eligibility and locations